Sensitization of the myofilaments and its implication for treatment in human heart failure;Wenn die myofilamente sensibel werden: Ca2+-sensitizer zur therapie der herzinsuffizienz

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 15, 2005, Pages 969-973

  Schwinger, Robert H G ^a   Brixius, K ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,5,6 TETRAHYDRO 5 METHYL 6 PHENYL 3,6 METHANO 1,5 BENZODIAZOCINE 2,4 DIONE; 4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; CALCIUM ION; CALCIUM SENSITIZER; DOBUTAMINE; LEVOSIMENDAN; N HYDROXY 5,6 DIMETHOXY 2 BENZO[B]THIOPHENECARBOXIMIDAMIDE; PIMOBENDAN;

CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CLINICAL TRIAL; DRUG MECHANISM; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; MYOFILAMENT; REVIEW; SENSITIZATION; TACHYCARDIA;

CALCIUM; CARDIOTONIC AGENTS; HEART; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; MICROFILAMENTS; MYOCARDIUM; OXYGEN CONSUMPTION; PYRIDAZINES; QUINOLINES; THIADIAZINES;

EID: 17644404830     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-866773     Document Type: Review

References (44)

1. Andrew P. Diastolic heart failure demystified. Chest 2003; 124: 744-753
2. Beuckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992; 85: 1046-1055
3. Boknik P, Neumann J, Kaspareit G et al. Mechanisms of the contractile effects of levosimendan in the mammalian heart. J Pharmacol Exp Ther 1997; 280: 277-283
4. 2+ transients in the human heart. J Appl Physiol 1997; 83: 652-660
5. Brixius K, Reicke S, Schwinger RHG. Beneficial effects of the Ca(2+) sensitizer levosimendan in human myocardium. Am J Physiol 2002; 282: H131-H137
6. Cleland JG, Ghosh J, Freemantle N et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004; 6: 501-508
7. Du Toit EF, Muller CA, McCarthy J, Opie LH. Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 1999; 290: 505-514
8. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995; 77: 107-113
9. 2+ sensitizers-update 2001. Cardiovasc Drugs Ther 2001; 15: 397-403
10. Felker GM, Benza RL, Chandler AB et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003; 41: 997-1003
11. Follath F. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial. Ital Heart J 2003; 4(Suppl 2): 34S-38S
12. Follath F, Cleland JG, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202
13. Gruhn N, Nielsen-Kudsk JE, Theilgaard S et al. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998; 31: 741-749
14. Hagemeijer F, Brand HJ, van Mechelen R. Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1989; 63: 571-576
15. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995; 27: 1859-1866
16. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998; 98: 2141-2147
17. Hiro J, Hiro T, Reid CL, Ebrahimi R, Matsuzaki M, Gardin JM. Safety and results of dobutamine stress echocardiography in women versus men and in patients older and younger than 75 years of age. Am J Cardiol 1997; 80: 1014-1020
18. Hohnloser SH, Zehender M, Geibel A, Meinertz T, Just H. Electrophysiologic effects of enoximone in patients with congestive heart failure. J Cardiovasc Pharmacol 1989; 14 (Suppl 1): S29-S32
19. Holbrook M, Coker SJ. Comparison of the effects of isobutylmethylxanthine and milrinone on ischaemia-induced arrhythmias and platelet aggregation in anaesthetized rabbits. Br J Pharmacol 1989; 98: 318-324
20. Holubarsch C, Hasenfuss G, Just H, Alpert NR. Positive inotropism and myocardial energetics: influence of beta receptor agonist stimulation, phosphodiesterase inhibition, and ouabain. Cardiovasc Res 1994; 28: 994-1002
21. Holubarsch C, Hasenfuss G, Thierfelder L, Heiss HW, Just H. Vasodilation and positive inotropic effect of the phosphodiesterase inhibitor enoximone. Z Kardiol 1991; 80(Suppl 4): 35-40
22. Korbmacher B, Sunderdiek U, Arnold G, Schulte HD, Schipke JD. Improved ventricular function by enhancing the Ca++ sensitivity in normal and stunned myocardium of isolated rabbit hearts. Basic Res Cardiol 1994; 89: 549-562
23. Labriola C, Siro-Brigiani M, Carrata F, Santangelo E, Amantea B. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther 2004; 42: 204-211
24. 2+ in guinea-pig isolated ventricular myocytes. Eur J Pharmacol 1997; 339: 97-100
25. Lewis EF, Tsang SW, Fang JC et al. Frequency and impact of delayed decisions regarding heart transplantation on long-term outcomes in patients with advanced heart failure. J Am Coll Cardiol 2004; 43: 794-802
26. Lilleberg J, Ylonen V, Lehtonen L, Toivonen L. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J 2004; 38: 80-84
27. Lubbe WF, Podzuweit T, Opie LH. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J Am Coll Cardiol 1992; 19: 1622-1633
28. Lubsen J, Just H, Hjalmarsson AC et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996; 76: 223-231
29. Lynch JJ, Kitzen JM, Hoff PT, Lucchesi BR. Effects of pimobendan (UD-CG 115 BS), a new positive inotropic agent, on ventricular tachycardia and ischemic ventricular fibrillation in a conscious canine model of recent myocardial infarction. J Cardiovasc Pharmacol 1988; 12: 547-554
30. Matsui K, Kiyosue T, Wang JC, Dohi K, Arita M. Effects of pimobendan on the L-type Ca2+ current and developed tension in guinea-pig ventricular myocytes and papillary muscle: comparison with IBMX, milrinone, and cilostazol. Cardiovasc Drugs Ther 1999; 13: 105-113
31. Maury P, Baixas C, Roncalli J et al. Resumption of atrioventricular conduction by levosimendan after radiofrequency ablation of the AV node. Pacing Clin Electrophysiol 2004; 27: 1314-1316
32. Moiseyev VS, Poder P, Andrejevs N et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23: 1422-1432
33. Mori M, Takeuchi M, Takaoka H, Yokoyama M. Lusitropic effects of a Ca2+ sensitization with a new cardiotonic agent, MCI-154, on diseased human hearts. Cardiovasc Res 1995; 30: 915-922
34. Pataricza J, Krassoi I, Hohn J, Kun A, Papp JG. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 2003; 17: 115-121
35. Poder P, Eha J, Sundberg S. Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study. J Clin Pharmacol 2004; 44: 1143-1150
36. 2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 1998; 30: 1115-1128
37. Shahid M, Nicholson CD. Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram. Naunyn Schmiedebergs Arch Pharmacol 1990; 342: 698-705
38. Shakar SF, Abraham WT, Gilbert EM et al. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998; 31: 1336-1340
39. Szilagyi S, Pollesello P, Levijkovi J et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 2004; 486: 67-74
40. 2+ sensitizer, MCl-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor. Am Heart J 1997; 133: 283-289
41. The EPOCH Study Group. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure (EPOCH study). Circ J 2002; 66: 149-157
42. Usta C, Puddu PE, Papalia U et al. Comparision of the inotropic effects of levosimendan, rolipram, and dobutamine on human atrial trabeculae. J Cardiovasc Pharmacol 2004; 44: 622-625
43. 2+ current in rat ventricular myocytes. Br J Pharmacol 1999; 127: 65-74
44. Westfall MV, Wahler GM, Fujino K, Solaro RJ. Electrophysiological actions of the pimobendan metabolite, UD-CG 212 Cl, in guinea pig myocardium. J Pharmacol Exp Ther 1992; 260: 58-63